Skip to main content

Building patient-focused companies around transformative technologies.

Hibiscus BioVentures provides the Technology, Capital and People necessary to build transformative biotechnology companies.

Our Mission

Committed to significantly moving patient care forward by supporting development of commercially viable therapeutics and diagnostics. Providing all the resources necessary in-house to identify major unmet medical needs and drive impactful solutions for patients.


Hibiscus Biotechnology Logo

Venture studio focused on building companies from the ground up around innovative technologies.

Hibiscus Capital Management Logo

Patient-focused venture capital arm investing in transformative biotechnology companies.

Our Latest News

Mayo Clinic Joins With Industry Groups to Launch Biotech Accelerator

| All, Mayflower BioVentures | No Comments
Mayo Clinic has joined with two industry partners to start an accelerator for cell- and gene-therapy startups, part of an effort the healthcare provider is making to expand in this…

Mayo Clinic, Hibiscus BioVentures and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator

| All, Mayflower BioVentures | No Comments
ROCHESTER, Minn. and ROCKVILLE, Md., Aug. 31, 2022 /PRNewswire/ -- Mayo Clinic, Hibiscus BioVentures (Hibiscus) and Innoforce announce the launch of Mayflower BioVentures, a cell and gene therapy accelerator dedicated to identifying and forming companies around…
3DBio Therapeutics 3-D Printed Ear

3DBio Therapeutics and the Microtia-Congenital Ear Deformity Institute Conduct Human Ear Reconstruction Using 3D-Bioprinted Living Tissue Implant in a First-in-Human Clinical Trial

| 3DBio Therapeutics, All | No Comments
- AuriNovo™ an investigational, 3D-bioprinted implant was created using a proprietary process leveraging the patient’s own tissue to generate an implantable ear - - Phase 1/2a clinical trial enrolling patients…